L-dopa and dyskinesias in normal monkeys

Movement Disorders

Volumn 14, Issue SUPPL. 1, 1999, Pages 9-12

  Pearce, Ronald K B ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DYSKINESIA; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PARKINSONISM; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; HAPLORHINI; LEVODOPA;

EID: 0032708939     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Chase TN, Holden EM, Brody JA. L-Dopa-induced dyskinesias: comparison in parkinsonism-dementia and amyotrophic lateral sclerosis. Arch Neurol 1973;29:328-330.
2. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
3. Cotzias GC, Mena I, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969; 280:337-345.
4. Duvoisin RC. Hyperkinetic reactions with L-dopa. In: Yahr MD, ed. Current Concepts in the Treatment of Parkinsonism. New York, NY: Raven Press, 1974:203-210.
5. Mones RJ, Elizan TS, Siegel GJ. Analysis of L-dopa induced dyskinesias in 51 patients with parkinsonism. J Neurol Neurosurg Psychiatry 1971;34:668-673.
6. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969;21: 343-354.
7. Bédard PJ, Gomez-Mancilla B, Blanchette P, Gagnon C, Di Paolo T. L-Dopa-induced dyskinesias: facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 1992;19:134-137.
8. Null JG. L-Dopa-induced dyskinesias: review, observations, and speculations. Neurology 1990;40:340-345.
9. Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic L-dopa therapy in Parkinson's disease. Neurology 1989;39(suppl 2):11-19.
10. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-956.
11. Quinn N, Critchley M, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-92.
12. Klawans HL. Use of L-dopa in the detection of presymptomatic Huntington's chorea. N Engl J Med 1972;286:1332-1334.
13. Mena I, Court J, Fuenzalida PS, Papavasiliou PS, Gellene R. Modification of chronic manganese poisoning: treatment with L-dopa or 5-OH tryptophane. N Engl J Med 1970;282:5-9.
14. Rajput AH, Fenton ME, Birdi S, Macaulay R. Is L-dopa toxic to human substantia nigra? Mov Disord 1997;12:634-638.
15. Riley DE. Lack of dyskinesias or parkinsonism after long term exposure to L-dopa. Mov Disord 1997;12(suppl 1):P322.
16. Arts N, Van de Vlasakker C, Tacke T, Horstink M. Is L-dopa harmful? Lancet 1991;338:1210-1211.
17. Lieberman AN, Goodgold AL, Goldstein M. Treatment failures with L-dopa in parkinsonism. Neurology 1972;22:1205-1210.
18. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving L-dopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-68.
19. Goodwin FK, Murphy DL, Brodie KH, Bunney WE. L-Dopa, catecholamines, and behaviour: a clinical and biochemical study in depressed patients. Biol Psychiatry 1970;2:342-366.
20. Bédard PJ, DiPaolo T, Falardeau P, Boucher R. Chronic treatment with L-dopa, but not bromocriptine induces dyskinesias in MPTP-treated parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res 1986;379:294-299.
21. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys. Psychopharmacology 1990;102:21-27.
22. Schneider JS. L-Dopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989;34:193-196.
23. Nutt JG, Holford NHG. The response to L-dopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-573.
24. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Nigrostriatal damage is required for induction of dyskinesias by L-dopa in squirrel monkeys. Clin Neuropharmacol 1990;13:448-458.
25. Pearce RKB, Jackson M, Smith L, Jenner P, Marsden CD. Chronic L-dopa administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov Disord 1995;10:731-740.
26. Mones RJ. L-Dopa-induced dyskinesias in the normal rhesus monkey. Mt Sinai J Med 1972;39:197-201.
27. Mones RJ. Experimental dyskinesias in normal rhesus monkey. In: Barbeau A, Chase TN, Paulson GW, eds. Advances in Neurology, vol 1. New York, NY: Raven Press, 1973:665-669.
28. Mones RJ, Pasik P, Pasik T, Wilk S. The modification of L-dopa-induced dyskinesias in the monkey by unilateral nigral lesions. Trans Am Neurol Assoc 1973;98:234-237.
29. Paulson GW. Dyskinesias in monkeys. In: Barbeau A, Chase TN, Paulson GW, eds. Advances in Neurology, vol 1. New York, NY: Raven Press, 1973:647-650.
30. Sassin JF, Taub S, Weitzman ED. Hyperkinesia and changes in behaviour produced in normal monkeys by L-dopa. Neurology 1972;22:1122-1125.
31. Sassin JF. Drug-induced dyskinesias in monkeys. In: Meldrum BS, Marsden CD, eds. Advances in Neurology, vol 10. New York, NY: Raven Press, 1975:47-54.
32. Pearce RKB, Heikkilä, Lindén IB, Jenner P, Marsden CD. Repeated L-dopa administration to normal monkeys induces choreic and dystonic dyskinesias. Neuroscience. Submitted for publication.
33. Rupniak NMJ, Tye SJ, Steventon MJ, Boyce S, Iversen SD. Spontaneous orofacial dyskinesias in a captive cynomolgus monkey: implications for tardive dyskinesias. Mov Disord 1990;5:314-318.
34. Klawans HL, Goetz C, Nausieda PA, Weiner WJ. L-Dopa-induced dopamine receptor hypersensitivity. Ann Neurol 1977;2:125-129.
35. Tang LC, Cotzias GC. L-3,4-Dihydroxyphenylalanine-induced hypersensitivity simulating features of denervation. Proc Natl Acad Sci USA 1977;74:2126-2129.
36. Pearce RKB. Dopamine D1 receptor agonists and dopamine reuptake blockers: new treatment stratagems for Parkinson's disease. Expert Opinion on Therapeutic Patents 1996;6:949-953.
37. Blanchet PJ, Calon F, Martel JC, et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995;272:854-859.
38. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie L-dopa or dopamine agonist-induced dyskinesias in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990;5:100-108.
39. Blanchette P, Bédard PJ, Matsumura M, Richard H, Filion M. Pathophysiology of L-dopa-induced dyskinesias: changing concepts. In: Percheron G, ed. The Basal Ganglia IV. New York, NY: Plenum Press, 1994:539-548.
40. Juncos JL, Thomas ME, Raisman R, et al. Continuous and intermittent L-dopa differentially affect basal ganglia function. Ann Neurol 1989;25:473-478.
41. Obeso JA, Grandas F, Herrero MT, Horowski R. Review: the role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 1994; 6:889-897.
42. Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology 1993;43(suppl 6):S23-S27.
43. Pearce RKB, Zeng B-Y, Jenner P, Marsden CD. Altered striatal preproenkephalin mRNA levels in normal macaque monkeys (Macaca fascicularis) with dyskinesias induced by chronic L-dopa administration. Br J Pharmacol 1995;116:78P.
44. Zeng B-Y, Pearce RKB, MacKenzie GM, Jenner P, Marsden CD. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesias in normal monkeys chronically treated with L-dopa. Neuroscience. Submitted for publication.
45. Pearce RKB, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesias than L-dopa in the MPTP-treated common marmoset. Mov Disord 1998;13:234-241.
46. Schuh LA, Bennett JP. Suppression of dyskinesias in advanced Parkinson's disease. I: continuous intravenous L-dopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993;43:1545-1550.